Home » VIOQUEST INITIATES CLINICAL TRIAL FOR VQD-002
VIOQUEST INITIATES CLINICAL TRIAL FOR VQD-002
VioQuest Pharmaceuticals has initiated a Phase I/IIa clinical trial to assess the safety and dosing of VQD-002, triciribine-phosphate (TCN-P).
This trial is being conducted in up to 20 patients with diverse solid tumors, where abnormal levels of phosphorylated Akt (protein kinase B) have been observed.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May